Infographic: Efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative age-related macular degeneration using the Lumithera Valeda Light Delivery System: 13-month results from the LIGHTSITE III trial | Synapse
March 3, 2026Open Access
Infographic: Efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative age-related macular degeneration using the Lumithera Valeda Light Delivery System: 13-month results from the LIGHTSITE III trial
Key Points
Efficacy results show significant improvements in visual function after 13 months of treatment.
Safety evaluation indicates a low incidence of adverse events, with minimal side effects reported.
Assessment using the Lumithera Valeda Light Delivery System provides innovative treatment for retinal health.
Findings highlight the importance of this approach for nonexudative age-related macular degeneration patients.